Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Non-Current Assets: 2019-2024

Historic Non-Current Assets for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to $225.7 million.

  • Beam Therapeutics' Non-Current Assets fell 5.89% to $212.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $212.5 million, marking a year-over-year decrease of 5.89%. This contributed to the annual value of $225.7 million for FY2024, which is 9.25% down from last year.
  • According to the latest figures from FY2024, Beam Therapeutics' Non-Current Assets is $225.7 million, which was down 9.25% from $248.7 million recorded in FY2023.
  • Beam Therapeutics' Non-Current Assets' 5-year high stood at $248.8 million during FY2022, with a 5-year trough of $143.4 million in FY2020.
  • For the 3-year period, Beam Therapeutics' Non-Current Assets averaged around $241.1 million, with its median value being $248.7 million (2023).
  • Its Non-Current Assets has fluctuated over the past 5 years, first surged by 132.89% in 2020, then declined by 9.25% in 2024.
  • Over the past 5 years, Beam Therapeutics' Non-Current Assets (Yearly) stood at $143.4 million in 2020, then skyrocketed by 40.52% to $201.4 million in 2021, then grew by 23.52% to $248.8 million in 2022, then fell by 0.06% to $248.7 million in 2023, then dropped by 9.25% to $225.7 million in 2024.